Introduction {#s1}
============

Over the last century, dramatic changes moving toward a sedentary lifestyle, and a high-fat and high-sugar diet, have radically affected human metabolic health status. Chronic metabolic diseases, such as obesity, type 2 diabetes (T2D), and non-alcoholic fatty liver disease (NAFLD), have been increasing at an alarming rate globally in both developed and developing countries ([@B34]). The global prevalence of NAFLD is estimated to be 24% at present, with the highest rates in South America (31%) and the Middle East (32%), followed by Asia (27%), the USA (24%), and Europe (23%) ([@B133]). According to a global report on diabetes by the World Health Organization (WHO) ([@B124]), the prevalence of diabetes is estimated to be 8.5% of the global population or 422 million individuals in 2014. Among diabetic patients, 70−80% have NAFLD ([@B112]; [@B125]). Usually, NAFLD and T2D coexist and act synergistically to drive adverse outcomes in clinical practice. The presence of NAFLD increases the incidence of T2D and accelerates the development of complications in the latter ([@B100]; [@B113]; [@B114]; [@B3];[@B82]). Meanwhile, the presence of T2D increases the likelihood of progression of NAFLD to the more severe forms of liver disorders, such as non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma ([@B2]; [@B121]).

However, NAFLD is a heterogeneous disease that is influenced by multiple factors, including age, gender, ethnicity, genetic predisposition, and metabolic status ([@B133]). A proportion of individuals develops NAFLD in the absence of obesity and insulin resistance ([@B132]). Recent studies have found that several gene variants in the patatin-like phospholipase domain-containing 3 (PNPLA3) ([@B89]), transmembrane 6 superfamily member 2 protein (TM6SF2) ([@B55]), glucokinase regulatory protein (GCKR), protein phosphatase 1 regulatory subunit 3B (PPP1R3B), neurocan (NCAN), lysophospholipase-like 1 (LYPLAL1) ([@B108]), and membrane-bound O-acyltransferase domain-containing 7 (MBOAT7) ([@B66]) significantly increase the risk of NAFLD. Among them, several gene variants are associated with disproportionate increase in the risks of NAFLD and diabetes. For example, PNPLA3 rs738409 GG gene variant carriers have 73% more liver fat than non-carriers ([@B105]), but are not more likely to have T2D according to the NASH CRN database ([@B107]) and Shanghai Changfeng Study ([@B130]); only a small increase in the risk of T2D was observed in 100,323 people from a publicly available T2D genome-wide association studies (GWAS) database (OR 1.04 \[1.01−1.07\], *P* = 0.0045) ([@B25]). Moreover, the PNPLA3 gene variant was even associated with a decreased risk of T2D in the NAFLD patients selected from the NASH CRN study ([@B107]) and a Chinese prospective cohort after adjusting for liver fat content and its changes over time ([@B129]). Another NAFLD-related TM6SF2 rs58542926 C \> T gene variant is associated with an average of a 2.1-fold higher risk of NAFLD than non-carriers according to a recent meta-analysis ([@B85]). However, the TM6SF2 gene variant is reported to be accompanied by conserved insulin sensitivity and lower serum triglyceride levels in two Finnish cohorts ([@B137]; [@B103]), a 20−40% increase in the incidence of T2D in the METSIM and FINRISK studies ([@B46]), and a small increase in the risk of diabetes in 452,244 individuals from 54 studies (OR 1.07 \[1.05−1.10\], *P* = 4.8 × 10^−12^) ([@B65]). Other NAFLD-related gene variants, such as LYPLAL1 and MBOAT7, showed no increase in the risk of diabetes ([@B25]; [@B103]).

This review attempts to demonstrate the clinical and pathophysiological connections between NAFLD and T2D, as well as to explore the disproportionate development of NAFLD and diabetes in individuals with specific genetic variations. We will also review the available evidence regarding the influence of the gene variants on the individual response to lifestyle intervention and drug treatment in patients with NAFLD.

NAFLD Increases Risks of T2D {#s2}
============================

The prevalence of diabetes among the NAFLD and NASH patients is estimated to be 22.51% and 43.63%, respectively, which is much higher than the prevalence of diabetes in the general population (8.5%) ([@B124]; [@B134]). The causal relationship between NAFLD and T2D was initially recognized when high alanine aminotransferase (ALT) was found to predict the development of T2D in Pima Indians ([@B119]). So far, a large number of prospective, population-based cohort studies have demonstrated that the elevation of serum liver enzymes could increase the risk of T2D, independent of other common risk factors (such as diet and lifestyle) in populations from different ethnicities ([@B35]; [@B53]; [@B13]). However, these studies are still limited because most NAFLD patients have normal transaminase levels and complex reasons for liver enzyme elevation. Later, several cohort studies further showed that NAFLD diagnosed by ultrasonography is associated with a 33% to a five-fold increased risk of T2D in different populations with various follow-up periods and severity of NAFLD ([@B12]; [@B9]). In the last decade, advances in non-invasive methods for measuring liver fat content have enabled studies on the quantitative relationship between NAFLD and T2D. Based on the liver fat content measured by proton magnetic resonance spectroscopy (^1^H-MRS), Cusi et al. found a clear threshold of the liver fat content of ∼6 ± 2%, after which metabolic disorders such as muscle insulin resistance, hypertriglyceridemia, and hypo-high-density lipoprotein cholesterolemia become fully established ([@B17]). The Shanghai Changfeng Community Study also found that liver fat content \> 10% by a quantitative ultrasound method was associated with increased systemic insulin resistance and diabetes ([@B128]). Taken together, these findings highlight the importance of NAFLD in the occurrence of diabetes. Indeed, prior to the onset of diabetes, the presence of NAFLD is already associated with insulin resistance and elevated nocturnal blood glucose ([@B16]). Histological liver steatosis grades are inversely associated with hepatic and skeletal muscle insulin sensitivity measured by a euglycemic hyperinsulinemic clamp with 3-\[^3^H\]-glucose in non-diabetic individuals ([@B61]).

Concomitant NAFLD in diabetic patients makes it difficult to achieve good blood glucose control ([@B4]) and can aggravate a series of extra-hepatic complications. It has been reported that NAFLD increases the risk of cardiovascular disease by 1.96 (95% CI 1.4−2.7)-fold^9^, chronic kidney disease by 1.87 (95% CI 1.3−4.1)-fold, and proliferative/laser-treated retinopathy by 1.75 (95% CI 1.1−3.7)-fold^10^ in diabetic patients and the distal symmetric polyneuropathy by 5.32 (95% CI 3.1−9.3)-fold in diabetic patients with type 1 diabetes ([@B67]). In a large-scale prospective study based on the US National Health and Nutrition Examination Survey in 1988−1994, advanced fibrosis defined by a high NAFLD fibrosis score was also highly associated with increased cardiovascular disease mortality (HR 3.46 \[1.91−6.25\]) ([@B47]).

The complex interactions between NAFLD, visceral adiposity, and insulin resistance make it difficult to distinguish the precise mechanisms underlying the increased risk of diabetes in patients with NAFLD. It is likely that expanded and inflamed visceral adipose tissue initiates multiple factors that are potentially involved in the development of insulin resistance and NAFLD, such as free fatty acids and inflammatory adipocytokines ([@B101]). The liver is the main target organ for ectopic fat accumulation, and excessive free fatty acid (FFA) flux into the liver will substantiate insulin resistance by causing lysosomal instability, induction of NF-κB, and activation of TNFα ([@B30]) and cAMP/PKA pathway ([@B45]), or by activating NLRP3-mediated IL-1β and IL-18 production ([@B87]). Diacylglycerol (DAG), an intermediate of liver fat synthesis, also inhibits the liver insulin signaling through activation of protein kinase Cε (PKCε) and c-Jun N-terminal kinase (JNK) ([@B40]). As a compensatory mechanism, hepatocytes increase mitochondrial β-oxidation to limit FFA, and the lipid overload will further impair mitochondria antioxidant capacity, cause oxidative stress and mitochondrial leakage, and finally aggravate insulin resistance ([@B50]). Under conditions of hepatic insulin resistance, the *de novo* lipogenesis can be stimulated both by insulin, *via* sterol regulatory element-binding-protein 1c (SREBP-1c) ([@B115]), and by glucose, *via* carbohydrate response element-binding protein (ChREBP) ([@B58]). Thus, the interaction between liver steatosis and insulin resistance sets up a vicious cycle to promote the development of both NAFLD and T2D. Several recent studies also demonstrate that liver steatosis alters the secretion of a series of hepatokines with diabetogenic properties, such as fetuin A ([@B80]), fetuin B ([@B69]), RBP4 ([@B77]), selenoprotein P ([@B72]), DPP4 ([@B14]), and HFREP1 ([@B127]). These hepatokines can alter metabolism in liver, muscle, adipose tissue, and pancreas to induce insulin resistance ([**Figure 1**](#f1){ref-type="fig"}).

![The pathophysiological connections between non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D). NAFLD contributes to the development of T2D by increasing glucose production in the liver and exacerbating hepatic insulin resistance through the activation of hepatic protein kinase Cε and some liver-secreted proteins with diabetogenic properties, such as fetuin A, fetuin B, RBP4, selenoprotein P, DPP4, and HFREP1. Intrahepatic fat accumulation activates liver inflammation. It further promotes the development of atherogenic dyslipidemia \[increased small, dense low-density lipoprotein (LDL) particles, triglycerides, and decreased high-density lipoprotein (HDL) cholesterol\] and hypertension (activation of the renin-angiotensin-aldosterone system). It also induces systemic inflammatory status (increased CRP, IL-6, TNF, and reactive oxygen species) and a coagulation mechanism (increased fibrinogen, factor VII, and PAI-1). All the procedures play important roles in the development of diabetic macrovascular and microvascular complications. On the other hand, T2D and systemic insulin resistance promote an increase of free fatty acid flux from peripheral tissues to the liver, leading to the development and progression of NAFLD. Furthermore, T2D drives the progression of NAFLD from simple steatosis to non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma through multiple mechanisms, including direct hepatocyte lipotoxicity, hepatocellular oxidative stress due to increased oxidation of free fatty acids, endoplasmic reticulum stress, release of inflammatory cytokines by hepatic Kupffer cells and peripheral adipocytes, hepatocellular apoptosis and necrosis, and hepatocellular regenerative response.](fphar-10-00877-g001){#f1}

Liver steatosis promotes atherogenic dyslipidemia \[increased small, dense low-density lipoprotein (LDL) particles, triglycerides, and decreased high-density lipoprotein (HDL) cholesterol\] ([@B7]), activates intrahepatic and systemic inflammation \[increased C-reactive protein (CRP), interleukin 6 (IL-6), tumor necrosis factor (TNF), intercellular adhesion molecule 1, and P-selectin\] ([@B30]; [@B32]) and the renin-angiotensin-aldosterone system (RAS) ([@B79]), and disturbs the coagulation mechanism (increased fibrinogen, factor VII, and PAI-1) ([@B118]). All the NAFLD-related pathogenic mechanisms mentioned above may contribute to the increased risks of diabetic macrovascular and microvascular complications ([**Figure 1**](#f1){ref-type="fig"}).

T2D Increases the Risk of NAFLD Progression to NASH, Cirrhosis, and Hepatocellular Carcinoma {#s3}
============================================================================================

T2D is one of the strongest clinical predictors of the progression of NAFLD to NASH and cirrhosis ([@B1]).Current estimates indicate that about 10−20% of NAFLD patients will develop into nonalcoholic steatohepatitis (NASH), thus increasing the risk of liver advanced fibrosis or cirrhosis ([@B57]). The presence of T2D increases the risk of NASH by two- to three-fold ([@B86]). It has been reported that T2D is associated with up to 17.7% advanced liver fibrosis measured by transient elastography ([@B49]; [@B54]), and 7.1% advanced fibrosis defined by magnetic resonance elastography (MRE) ≥ 3.6 kPa ([@B27]). Studies based on liver histology find that a proportion of patients with T2D exhibits NASH up to 80% and advanced fibrosis to 30−40% ([@B15]). There is a great difference in clinical outcomes between NAFLD and NASH patients, and the progression of NAFLD to NASH tremendously increases the annual incidences of liver-specific mortality and hepatic carcinoma from 0.77 and 0.44 per 1,000 person-year, respectively, to 11.77 and 5.29 per 1,000 person-year, respectively, in NAFLD patients ([@B133]). A US-based population study in 2010 reported that NAFLD and T2D were the first two common factors present in patients with hepatocellular carcinoma (HCC) ([@B92]), and the presence of diabetes alone can increase the risk of developing HCC two-to-three−-fold ([@B28]). Therefore, the presence of diabetes tremendously drives the progression of NAFLD to NASH, cirrhosis, and even HCC at the final stage. Many patients with NASH developing into HCC exhibit T2D and higher rates of metabolic disorders (such as obesity and hypertension) ([@B131]; [@B5]). Given the fact that T2D is one of the main conditions closely associated with the progression of NAFLD to NASH, cirrhosis, and HCC, some researchers claim that NAFLD is an overlooked complication of diabetes ([@B11]).

In patients with T2D, liver lipogenesis is elevated ([@B115]; [@B58]), and fatty acid oxidation ([@B93]) and triglyceride secretion *via* very low-density lipoprotein (VLDL) are decreased ([@B41]). Moreover, peripheral insulin resistance increases fatty acid release from adipose tissue ([@B48]), and the hepatic uptake of fatty acids is also upregulated under the insulin resistance status ([@B71]). Thus, NAFLD often coexists with T2D. Initially, the mild liver fat accumulation is an adaptive response to metabolic stress against the lipotoxicity of free fatty acids ([@B26]). However, on the background of continuous hepatic free fatty acid influx, various inflammatory pathways are activated with the increasing hepatic intracellular triglycerides ([@B97]). In NAFLD patients with T2DM, the progression of NAFLD to NASH, cirrhosis, and even HCC is then driven by multiple insults involving several mechanisms ([@B18]) ([**Figure 1**](#f1){ref-type="fig"}). The excessive hepatic FFA influx in T2D patients, such as palmitic acid, cholesterol, lysophosphatidylcholine, and ceramides, directly causes lipotoxicity and induces liver inflammation and fibrosis ([@B116]; [@B68]). The oxidation and metabolism of excessive FFAs in the liver further cause oxidative stress ([@B81]) and endoplasmic reticulum (ER) stress ([@B75]) that trigger hepatocellular damage and apoptosis. In addition, excessive FFAs in the liver, the release of inflammatory mediators from dysfunctional adipose tissue (such as MCP-1, IL-6, and TNFα) ([@B23]), and endotoxins derived from gut ([@B20]) in diabetic patients with NAFLD also activate hepatic Kupffer cells ([@B44]) and release liver inflammatory mediators (IL-1β, TNFα, IL-6) to promote liver injury and inflammation ([@B136]). Hepatocellular injury further activates the apoptotic and necrotic hepatocyte death pathways ([@B62]), and the persistence of this procedure ultimately leads to the activation of hepatic stellate cells, collagen deposition, and hepatic fibrosis ([@B126]). Recently, it has also been reported that insulin resistance can promote liver fibrosis through induction of lysyl oxidase-like 2 (Loxl2), independent of hepatic stellate cell activity ([@B24]). At the same time, the insulin resistance, oxidative stress, ER stress, liver inflammation, and hepatocyte death can also initiate the hepatocellular regenerative mechanism through a series of growth factors and activate multiple oncogenic signaling pathways, such as PI3K/PTEN/Akt, JAK/STAT, NF-kB, mTOR, 4HNE, and NRF-1, which further promote the development of HCC ([@B78]) ([**Figure 1**](#f1){ref-type="fig"}).

Disproportionate Development of NAFLD and T2D in Specific Gene Variant Carriers {#s4}
===============================================================================

The first evidence for the development of NAFLD in the absence of glucose metabolism disorders was found in a mouse model with overexpression of diacylglycerol acyltransferase 2 (DGAT2), an enzyme catalyzing the final step of hepatic triglyceride biosynthesis from DAG ([@B74]). These mice present obvious hepatic steatosis in the absence of any abnormalities in the plasma glucose and insulin resistance levels ([@B98]). Further, human studies have found that DGAT2 rs1944438 C \> T variant carriers have a smaller reduction in liver fat than non-carriers after a lifestyle intervention program, but their changes in insulin sensitivity are not different ([@B42]). Later, it was recognized that NAFLD-related hepatic insulin resistance is caused by an increase in hepatic DAG content ([@B40]). Therefore, individuals carrying the DGAT2 gain-of-function gene variants are associated with an increased risk of NAFLD with disproportionately conserved insulin sensitivity. Moreover, animal studies showed that inhibiting secretion of VLDL from the liver by genetic modification resulted in liver steatosis with conserved insulin sensitivity ([@B38]). Recent advances in GWAS have identified several gene variants that might contribute to the development of NAFLD in a proportion of patients with normal body mass index and a few features of metabolic syndromes, which include the gene variants in PNPLA3, TM6SF2, and MBOAT7 ([@B89]; [@B8]; [@B66]).

The PNPLA3 gene variant is the first and strongest common variant that is associated with NAFLD ([@B89]). The percentage of PNPLA3 gene variant carriers in the population varies from 25 to 70% in different ethnic groups ([@B89]; [@B120]). PNPLA3 rs738409 GG gene variant carriers have 73% more liver fat, a 3.2-fold higher risk of liver necro-inflammation ([@B105]), and a 1.9-fold higher risk of cirrhosis than PNPLA3 wild-type CC genotype carriers ([@B98]). PNPLA3 rs738409 CG heterozygous genotype carriers show only a small increase in liver fat content, which is between that of PNPLA3 CC and GG genotype carriers ([@B89]; [@B107]; [@B120]; [@B130]). PNPLA3 G allele is also associated with a 1.77-fold risk of HCC ([@B117]). However, the fasting or postload glucose and insulin levels do not differ between PNPLA3 gene variant carriers and non-carriers ([@B83]), even when insulin resistance level was measured by a hyperinsulinemic euglycemic clamp ([@B43]), although data from publicly available T2D GWAS database show a small increase in the risk of T2D in PNPLA3 gene variant carriers ([@B25]). The PNPLA3 rs738409 C \> G variant is also associated with reduced risk of cardiovascular disease and coronary heart disease-associated mortality ([@B70]). Therefore, the PNPLA3 rs738409 C \> G variant provides an example of a disproportionate progression of NAFLD and diabetes. It is now clear that PNPLA3 is located in lipid droplets ([@B21]), and it may interact with CGI-58 to interfere with adipose triglyceride lipase activity in the liver ([@B123]), as shown in [**Figure 2**](#f2){ref-type="fig"}. In the PNPLA3 rs738409 C \> G variant carriers, mutant PNPLA3 sequesters CGI-58, thus restricting its access to adipose triglyceride lipase and inhibiting the hydrolysis of stored lipids ([@B123]), which traps both triglyceride and DAG into cellular lipid droplets. It has also been reported that the profile of DAG species in PNPLA3^I148M^ hepatocytes is different from that of PNPLA3^wt^ hepatocytes ([@B90]), and an unaltered proportion of DAG (FA18:1) in PNPLA3 rs738409 C \> G variant carriers with fatty liver may correlate with their conserved insulin sensitivity ([@B36]; [@B31]). The subcellular localization and composition of DAG are important for its ability to mediate hepatic insulin resistance ([@B19]; [@B39]). Therefore, PNPLA3 rs738409 C \> G variant carriers, with a shift of DAG distribution and composition, would present seemingly paradoxical severe liver steatosis and conserved insulin sensitivity. This mechanism is supported by the phenotype of CGI-58 knockdown mice ([@B19]). The shift of liver lipid composition from saturated triglycerides to polyunsaturated triglycerides and a marked reduction in ceramides have been reported to contribute to preserved glucose metabolic status in PNPLA3 gene variant carriers ([@B64]; [@B73]). Although the PNPLA3 gene variant is associated with a disproportionate development of NAFLD and diabetes, the presence of diabetes in the PNPLA3 gene variant carriers still can amplify the genetic effect to drive the progression of NAFLD ([@B73]). Recent studies on the interaction between genetic and environmental factors on NAFLD show that adiposity or metabolic disorders can significantly amplify the effects of gene variants on NAFLD, from steatosis to hepatic inflammation and cirrhosis ([@B110]). In fact, the expression of PNPLA3 is directly regulated by the insulin-regulated transcription factor sterol regulatory element-binding protein-1c (SREBP-1c), and pathogenic PNPLA3 mutant products accumulate under conditions of obesity and insulin resistance, thus exacerbating liver steatosis, inflammation, and cirrhosis ([@B37]).

![Hepatic lipid metabolism under the condition of insulin resistance and the role of PNPLA3 and TM6SF2. Liver fat is derived from peripheral adipose tissue, *de novo* lipogenesis, and diet intake. In the state of insulin resistance, adipose triglyceride lipase (ATGL) is not fully inhibited by insulin, and free fatty acids are released continuously from the adipose to the liver. Hyperinsulinemia also induces the activity of sterol regulatory element-binding protein 1c (SREBP1c) and *de novo* liver lipid synthesis. The β-oxidation of fatty acid is reduced due to the inhibition of carnitine palmitoyl transferase-1 (CPT-1) by malonyl-coenzyme A generated from *de novo* lipogenesis. PNPLA3 interacts with CGI-58 to regulate the activity of ATGL and the hydrolysis of stored lipids. TM6SF2 functions to facilitate the assembly of very low-density lipoprotein (VLDL). However, mutant PNPLA3 constantly binds with CGI-58, inhibits liver ATGL, and causes liver steatosis and reduced release of insulin-resistance-inducing diacylglycerol (DAG) from lipid droplets. In addition, mutant TM6SF2 can inhibit the mobilization of neutral lipids and assembly of VLDL.](fphar-10-00877-g002){#f2}

The association between NAFLD and insulin resistance has been observed to be weakened in individuals with TM6SF2 gene variants ([@B137]). The frequency of the TM6SF2 rs58542926 C \> T gene variants has been reported to be 6.7% in Asians ([@B122]) and 7% in European populations ([@B51]). The TM6SF2 gene variant is associated with increased risks of NAFLD, NASH, and advanced fibrosis independent of age, body mass index (BMI), presence of diabetes, and PNPLA3 genotype status ([@B60]; [@B106]). Insulin sensitivity, as determined by the homeostasis model assessment for insulin resistance (HOMA-IR) or an oral glucose tolerance test, is not reduced in TM6SF2 gene variant carriers ([@B137]), and serum triglyceride and LDL cholesterol concentrations are lower compared with non-carriers ([@B103]). Although recent GWAS studies show that the TM6SF2 gene variant is associated with a small increase in the risk of diabetes in 452,244 individuals from 54 studies (OR 1.07 \[1.05−1.10\], *p* = 4.8 × 10^−12^) ([@B65]), the TM6SF2 gene variant has a much larger effect size on NAFLD (OR 2.13 \[1.36−3.30\], *p* = 0.0009) than T2D ([@B85]). The TM6SF2 gene variant is also associated with lower LDL cholesterol concentrations and a protection from cardiovascular disease ([@B59]). TM6SF2 is found to be located in the ER and Golgi complex and functions to mobilize neutral lipids for VLDL assembly, and the lipids accumulate in lipid droplets in its absence ([@B104]) ([**Figure 2**](#f2){ref-type="fig"}). Consistent with the animal models with inhibition of VLDL secretion, the TM6SF2 gene variant carriers present liver steatosis with no disorders of glucose metabolism ([@B38]), which may be related to the deficiency of polyunsaturated phosphatidylcholines and excess polyunsaturated FFA in the liver of TM6SF2 gene variant carriers ([@B63]).

Further evidence for NAFLD with a relative conservation of glucose metabolism can also be found in a small number of families with inherited gene mutations, such as familial hypobetalipoproteinemia ([@B6]), lysosomal acid lipase deficiency ([@B88]), adipose triglyceride lipase (ATGL) ([@B109]), and gene mutations related to fatty acid oxidation (such as medium-chain acyl-CoA dehydrogenase deficiency and carnitine palmitoyl transferase-1) ([@B111]).

Future of the NAFLD Treatment: Gene-Based Personalization {#s5}
=========================================================

For the majority of NAFLD patients, NAFLD and T2D/insulin resistance share common pathophysiological factors and coexist with each other, so several current therapies targeted at insulin resistance also demonstrate efficacy in treating NAFLD ([@B76]; [@B33]). Insulin sensitizers (such as metformin and thiazolidinediones) are one group of effective antidiabetic medication and have been proven to be effective in treating NAFLD in diabetic patients. Metformin is a first-line antidiabetic drug that improves both hepatic and peripheral insulin resistances. Although mounting evidence shows that metformin treatment does not consistently reduce fat content or inflammatory grades in NASH ([@B91]), its use in patients with T2D results in a 50% reduction in HCC incidence ([@B102]). Thiazolidinediones are peroxisome proliferator-activated receptor gamma (PPARγ) agonists and improve insulin resistance mainly by stimulating adipocyte differentiation ([@B84]). Studies on the effect of pioglitazone show a reduction of liver aminotransferase level and an improvement on liver histological steatosis and inflammation in NAFLD patients with T2D ([@B22]). Other novel treatments, such as glucagon-like peptide 1 (GLP-1) receptor agonists ([@B10]) and bariatric surgery ([@B56]), also show promising results in decreasing body weight and insulin resistance and improving NAFLD histological changes, but their effects on NAFLD still need to be further demonstrated in more populations with longer treatment periods. In patients with concomitant NAFLD and T2D, reduction in liver fat content can also help them achieve better blood glucose control and improve the long-term response to lifestyle intervention ([@B94]).

NAFLD patients with several specific gene variants feature NAFLD with a relative conservation of glucose metabolism, but there are still no formal recommendations for this type of NAFLD. Several preliminary clinical trials have indicated that NAFLD patients with specific gene variants respond differently to lifestyle and drug intervention. To take the PNPLA3 gene variant carriers as an example, a 6-day short-term hypocaloric low-carbohydrate diet led to a greater decrease in liver fat content in Finnish individuals with the PNPLA3 GG genotype than those with the PNPLA3 CC genotype (45% *vs*. 18%) ([@B96]). In a 12-month lifestyle intervention program with \>10% body weight reduction, PNPLA3 GG homozygotes showed a significantly greater reduction in liver fat content than PNPLA3 CG heterozygotes and CC homozygotes ([@B99]). In severely obese patients with NAFLD, the PNPLA3 G carriers had significantly greater improvement in hepatic steatosis 1 year after bariatric surgery with an average weight loss of 40 kg ([@B52]). However, the Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy (WELCOME) trial showed the opposite result that liver fat content was decreased due to DHA+EPA treatment only in PNPLA3 CC and CG, but not GG genotype carriers ([@B95]). A recent EFFECT-II study investigated the effects of dapagliflozin and omega-3 carboxylic acid on liver steatosis and, interestingly, found that compared with PNPLA3 wild-type genotype carriers, PNPLA3 gene variant carriers shower a smaller reduction in liver fat content in the dapagliflozin treatment group, similar liver fat reduction in the omega-3 carboxylic acid treatment group, and larger reduction in liver fat content in the combination treatment group ([@B29]). Many clinical trials are still ongoing to evaluate the difference among the NAFLD patients with different gene variants in their response to different NAFLD interventions. Although it is still an emerging new frontier to study gene variation and the efficacy of NAFLD treatment, all the current evidence indicates that a personalized treatment based on genetic classification is necessary.

Conclusion {#s6}
==========

It is clear that there is a complex bidirectional relationship between the progression of NAFLD and the development of T2D, and their interaction could result in an increase in both hepatic and diabetic mortalities in patients with concomitant NAFLD and T2D. For NAFLD patients with T2D, some currently available therapies targeting insulin resistance might be the best choice to improve both hepatic and metabolic outcomes. For NAFLD patients with specific gene variant and a disproportionate conservation of glucose metabolism, preliminary data indicate a different response to current NAFLD interventions. Therefore, more studies on the treatment of NAFLD in specific gene variant carriers are urgently needed, and a testing of NAFLD-related gene variants may be helpful to guide personalized treatment in the near future.
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